Our Portfolio

export-table

Export table

FILTERS

Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Dossier Availability
Select some options

PRODUCT NAME

THERAPEUTIC AREA

PHARMACEUTICAL
FORM

STRENGTH

REFERENCE
PRODUCT

DOSSIER
AVAILABILITY

Alimentary tract & metabolism
Film-coated tablets
10 mg/5 mg
25 mg/5 mg
Glyxambi/ Boehringer Ingelheim
2024 Q4
Alimentary tract & metabolism
Film-coated tablets
5/850 mg
5/1000 mg
Xigduo / Astra Zeneca
2022 Q4
Alimentary tract & metabolism
Film-coated tablets
5mg/500mg
5mg/850mg
5mg/1000 mg
12.5mg/500mg
12.5mg/850mg
12.5mg/1000mg
Synjardy / Boehringer Ingelheim
2025 Q1
Alimentary tract & metabolism
Film-coated tablets
2.5/500 mg
2.5/850 mg
2.5/1000 mg
Jentadueto / Boehringer Ingelheim
2022 Q4
Cardiovascular System
Tablets
5 mg
10 mg
Nebilet / Menarini
2022 Q4
Cardiovascular System
Film-coated tablets
24mg / 26mg
49mg / 51mg
97mg / 103mg
Entresto / Novartis
2022 Q4 (CA) / 2023 Q4 (EU)
Respiratory system
Inhalation powder
44 mcg
Seebri Breezhaler / Novartis
2023 Q2
Respiratory system
Inhalation powder
85/43 mcg
Ultibro Breezhaler / Novartis
2024 Q1
Antineoplastic & Immunomodulating Agents
Film-coated tablets
10 mg
20 mg
30 mg
Otezla / Celgene
2023 Q3 (EU)
Antineoplastic & Immunomodulating Agents
Prolonged-release tablet
11 mg
Xeljanz / Pfizer
Early stage
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
^ This product is not offered for sale or made available in Germany due to patent (SPC) protection.

DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

Our Portfolio

Empagliflozin* / Linagliptin*^

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Glyxambi/ Boehringer Ingelheim

STRENGTH

10 mg/5 mg
 | 25 mg/5 mg

DOSSIER AVAILABILITY

2024 Q4

Dapagliflozin* / Metformin (1)^

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Xigduo / Astra Zeneca

STRENGTH

5/850 mg
 | 5/1000 mg

DOSSIER AVAILABILITY

2022 Q4

Empagliflozin* / Metformin^

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Synjardy / Boehringer Ingelheim

STRENGTH

5mg/500mg
 |  5mg/850mg
 | 5mg/1000 mg
 | 12.5mg/500mg
 | 12.5mg/850mg
 | 12.5mg/1000mg

DOSSIER AVAILABILITY

2025 Q1

Linagliptin* / Metformin (2)^

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Jentadueto / Boehringer Ingelheim

STRENGTH

2.5/500 mg
 | 2.5/850 mg
 | 2.5/1000 mg

DOSSIER AVAILABILITY

2022 Q4

Nebivolol

THERAPEUTIC AREA

Cardiovascular System

PHARMACEUTICAL FORM

Tablets

REFERENCE PRODUCT

Nebilet / Menarini

STRENGTH

5 mg
 | 10 mg

DOSSIER AVAILABILITY

2022 Q4

Sacubitril / Valsartan (3)

THERAPEUTIC AREA

Cardiovascular System

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Entresto / Novartis

STRENGTH

24mg / 26mg
 | 49mg / 51mg
 | 97mg / 103mg

DOSSIER AVAILABILITY

2022 Q4 (CA) / 2023 Q4 (EU)

* Polpharma Group API

(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
^ This product is not offered for sale or made available in Germany due to patent (SPC) protection.

DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).